Are curcuminoids effective C-reactive protein-lowering agents in clinical practice? evidence from a meta-analysis

Phytotherapy Research

Volumn 28, Issue 5, 2014, Pages 633-642

  Sahebkar, Amirhossein ^a  

^a MASHHAD UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

anti inflammatory; atherosclerosis; coronary heart disease; Curcuma longa L; curcumin; turmeric

Indexed keywords

C REACTIVE PROTEIN; C3 COMPLEX; CURCUMIN; LONGVIDA; MERIVA; PLACEBO; UNCLASSIFIED DRUG;

CLINICAL EFFECTIVENESS; CLINICAL PRACTICE; CONTROLLED CLINICAL TRIAL (TOPIC); CORONARY ARTERY DISEASE; DRUG BIOAVAILABILITY; DRUG EFFICACY; HUMAN; META ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; REVIEW; SENSITIVITY ANALYSIS; SYSTEMATIC REVIEW; TREATMENT DURATION; TREATMENT OUTCOME;

CURCUMA LONGA;

ANTI-INFLAMMATORY; ATHEROSCLEROSIS; CORONARY HEART DISEASE; CURCUMA LONGA L; CURCUMIN; TURMERIC;

ANTI-INFLAMMATORY AGENTS; C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CLINICAL TRIALS AS TOPIC; CURCUMIN; DIETARY SUPPLEMENTS; HUMANS;

EID: 84899477785     PISSN: 0951418X     EISSN: 10991573     Source Type: Journal    
DOI: 10.1002/ptr.5045     Document Type: Review

References (84)

1. Aggarwal BB,. 2010. Targeting inflammation-induced obesity and metabolic diseases by curcumin and other nutraceuticals. Annu Rev Nutr 30: 173-199.
2. Ahuja S, Shankar P, Boylan M,. 2011. Curcumin's therapeutic properties in disease prevention. Agro Food Industry Hi-Tech 22: 26-28.
3. Albert MA,. 2007. Inflammatory biomarkers, race/ethnicity and cardiovascular disease. Nutr Rev 65: S234-238.
4. Anand P, Kunnumakkara AB, Newman RA, Aggarwal BB,. 2007. Bioavailability of curcumin: problems and promises. Mol Pharm 4: 807-818.
5. Ashour MN, Habib DF, Hanna RA, El-Dabaa MAT,. 2011. Beneficial effects of curcumin and ruta chalepensis on the antioxidant system and inflammation in hypercholesteromic rats. Aust J Basic Appl Sci 5: 2562-2567.
6. Bays HE, Davidson M, Jones MR, Abby SL,. 2006. Effects of colesevelam hydrochloride on low-density lipoprotein cholesterol and high-sensitivity C-reactive protein when added to statins in patients with hypercholesterolemia. Am J Cardiol 97: 1198-1205.
7. Begum AN, Jones MR, Lim GP, et al,. 2008. Curcumin structure-function, bioavailability, and efficacy in models of neuroinflammation and Alzheimer's disease. J Pharmacol Exp Ther 326: 196-208.
8. Belcaro G, Cesarone MR, Dugall M, et al,. 2010. Product-evaluation registry of meriva®, a curcumin-phosphatidylcholine complex, for the complementary management of osteoarthritis. Panminerva Med 52: S55-62.
9. Carson SD, Johnson DR,. 1990. Consecutive enzyme cascades: complement activation at the cell surface triggers increased tissue factor activity. Blood 762: 361-367.
10. Chainani-Wu N, Madden E, Lozada-Nur F, Silverman Jr. S,. 2012. High-dose curcuminoids are efficacious in the reduction in symptoms and signs of oral lichen planus. J Am Acad Dermatol 66: 752-760.
11. Chan KY, Boucher ES, Gandhi PJ, Silva MA,. 2004. HMG-CoA reductase inhibitors for lowering elevated levels of C-reactive protein. Am J Health Syst Pharm 61: 1676-1681.
12. Chen WF, Deng SL, Zhou B, Yang L, Liu ZL,. 2006. Curcumin and its analogues as potent inhibitors of low density lipoprotein oxidation: H-atom abstraction from the phenolic groups and possible involvement of the 4-hydroxy-3-methoxyphenyl groups. Free Radic Biol Med 40: 526-535.
13. Clearfield MB,. 2005. C-reactive protein: a new risk assessment tool for cardiovascular disease. J Am Osteopath Assoc 105: 409-416.
14. Coban D, Milenkovic D, Chanet A, et al,. 2012. Dietary curcumin inhibits atherosclerosis by affecting the expression of genes involved in leukocyte adhesion and transendothelial migration. Mol Nutr Food Res 56: 1270-1281.
15. Cuomo J, Appendino G, Dern AS, et al,. 2011. Comparative absorption of a standardized curcuminoid mixture and its lecithin formulation. J Nat Prod 74: 664-669.
16. Devadasu VR, Wadsworth RM, Kumar MNVR,. 2011. Protective effects of nanoparticulate coenzyme Q 10 and curcumin on inflammatory markers and lipid metabolism in streptozotocin-induced diabetic rats: A possible remedy to diabetic complications. Drug Delivery Transl Res 1: 448-455.
17. DiSilvestro RA, Joseph E, Zhao S, Bomser J,. 2012. Diverse effects of a low dose supplement of lipidated curcumin in healthy middle aged people. Nutr J 11: 79. doi: 10.1186/1475-2891-11-79.
18. Engler RL, Schmid-Schonbein GW, Pavelec RS,. 1983. Leukocyte capillary plugging in myocardial ischemia and reperfusion in the dog. Am J Pathol 111: 98-111.
19. Epstein J, Sanderson IR, MacDonald TT,. 2010. Curcumin as a therapeutic agent: The evidence from in vitro, animal and human studies. Br J Nutr 103: 1545-1557.
20. Fan J, Li X, Yan YW, et al,. 2012. Curcumin attenuates rat thoracic aortic aneurysm formation by inhibition of the c-jun N-terminal kinase pathway and apoptosis. Nutrition 28: 1068-1074.
21. Fu T, Borensztajn J,. 2002. Macrophage uptake of low-density lipoprotein bound to aggregated C-reactive protein: possible mechanism of foam-cell formation in atherosclerotic lesions. Biochem J 366: 195-201.
22. Gewurz H, Zhang XH, Lint TF,. 1995. Structure and function of the pentraxins. Curr Opin Immunol 7: 54-64.
23. Ghayour-Mobarhan M, Sahebkar A, Starkey BJ, et al,. 2008. Investigation of the effects of statin therapy on serum vitamin E status in patients with dyslipidemia. Pakistan J Nutr 7: 561-565.
24. Goldberg RB, Guyton JR, Mazzone T, et al,. 2006. Ezetimibe/simvastatin vs atorvastatin in patients with type 2 diabetes mellitus and hypercholesterolemia. Mayo Clin Proc 81: 1579-1588.
25. Goldberg AC, Bays HE, Ballantyne CM, et al,. 2009. Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia. Am J Cardiol 103: 515-522.
26. Gota VS, Maru GB, Soni TG, Gandhi TR, Kochar N, Agarwal MG,. 2010. Safety and pharmacokinetics of a solid lipid curcumin particle formulation in osteosarcoma patients and healthy volunteers. J Agric Food Chem 58: 2095-2099.
27. Hiuge A, Tenenbaum A, Maeda N, et al,. 2007. Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level. Arterioscler Thromb Vasc Biol 27: 635-641.
28. Holt PR, Katz S, Kirshoff R,. 2005. Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci 50: 2191-2193.
29. Hozo SP, Djulbegovic B, Hozo I,. 2005. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol 20: 13.
30. Jadad AR, Moore RA, Carroll D, et al,. 1996. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17: 1-12
31. Jomezadeh V, Mohammadpour AH, Rajabi O, Tavassoli A, Maddah G,. 2012. Evaluation of curcumin effects on post-operative peritoneal adhesion in rats. Iran J Basic Med Sci 15: 1162-1167.
32. Jones PH, Davidson MH, Kashyap ML, et al,. 2009. Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study. Atherosclerosis 204: 208-215.
33. Joshi PH, Jacobson TA,. 2010. Therapeutic options to further lower C-reactive protein for patients on statin treatment. Curr Atheroscler Rep 12: 34-42.
34. Jurenka JS,. 2009. Anti-inflammatory properties of curcumin, a major constituent of curcuma longa: A review of preclinical and clinical research. Alternat Med Rev 14: 141-153.
35. Kapakos G, Youreva V, Srivastava AK,. 2012. Cardiovascular protection by curcumin: Molecular aspects. Indian J Biochem Biophys 49: 306-315.
36. Kastelein JJ, Akdim F, Stroes ES, et al,. 2008. Simvastatin with or without ezetimibe in familial hypercholesterolemia. N Engl J Med 358: 1431-1443.
37. Kilgore KS, Friedrichs GS, Homeister JW, Lucchesi BR,. 1994. The complement system in myocardial ischemia/reperfusion injury. Cardiovasc Res 28: 437-444.
38. Lagrand WK, Visser CA, Hermens WT, et al,. 1999. C-reactive protein as a cardiovascular risk factor: more than an epiphenomenon? Circulation 100: 96-102.
39. Li HL, Liu C, de Couto G, et al,. 2008. Curcumin prevents and reverses murine cardiac hypertrophy. J Clin Invest 118: 879-893.
40. Lindahl B, Toss H, Siegbahn A, Venge P, Wallentin L, for the FRISC Study Group. 2000. Fragmin during instability in coronary artery disease: markers of myocardial damage and inflammation in relation to long-term mortality in unstable coronary artery disease. N Engl J Med 343: 1139-1147.
41. Liuzzo G, Biasucci LM, Gallimore JR, et al,. 1994. The prognostic value of C-reactive protein and serum amyloid a protein in severe unstable angina. N Engl J Med 331: 417-424.
42. Mackiewicz A, Speroff T, Ganapathi MK, Kushner I,. 1991. Effects of cytokine combinations on acute phase protein production in two human hepatoma cell lines. J Immunol 146: 3032-3037.
43. Marczylo TH, Verschoyle RD, Cooke DN, Morazzoni P, Steward WP, Gescher AJ,. 2007. Comparison of systemic availability of curcumin with that of curcumin formulated with phosphatidylcholine. Cancer Chemother Pharmacol 60: 171-177.
44. Menon VP, Sudheer AR,. 2007. Antioxidant and anti-inflammatory properties of curcumin. Adv Exp Med Biol 595: 105-125
45. Mohammadi A, Sahebkar A, Iranshahi M, et al,. 2013. Effects of supplementation with curcuminoids on dyslipidemia in obese patients: A randomized crossover trial. Phytother Res 27: 374-379.
46. Moher D, Liberati A, Tetzlaff J, Altman DG,. 2009. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ 339: b2535.
47. Montecucco F, Mach F,. 2009. Therapeutic approaches for reducing C-reactive protein (CRP) levels and the associated cardiovascular risk. Curr Chem Biol 3: 60-64.
48. Morrow DA, Rifai N, Antman EM, et al,. 1998. C-reactive protein is a potent predictor of mortality independently and in combination with troponin T in acute coronary syndromes: a TIMI 11A substudy. J Am Coll Cardiol 31: 1460-1465.
49. Motterlini R, Foresti R, Bassi R, Green CJ,. 2000. Curcumin, an antioxidant and anti-inflammatory agent, induces heme oxygenase-1 and protects endothelial cells against oxidative stress. Free Radic Biol Med 28: 1303-1312.
50. Nakou ES, Liberopoulos EN, Milionis HJ, Elisaf MS,. 2008. The role of C-reactive protein in atherosclerotic cardiovascular disease: an overview. Curr Vasc Pharmacol 6: 258-270.
51. Nieman DC, Cialdella-Kam L, Knab AM, Shanely RA,. 2012. Influence of red pepper spice and turmeric on inflammation and oxidative stress biomarkers in overweight females: a metabolomics approach. Plant Foods Hum Nutr 67: 415-421.
52. Nirmala C, Puvanakrishnan R,. 1996. Protective role of curcumin against isoproterenol induced myocardial infarction in rats. Mol Cell Biochem 159: 85-93.
53. Panahi Y, Sahebkar A, Amiri M, et al,. 2012a. Improvement of sulphur mustard-induced chronic pruritus, quality of life and antioxidant status by curcumin: Results of a randomised, double-blind, placebo-controlled trial. Br J Nutr 108: 1272-1279.
54. Panahi Y, Sahebkar A, Parvin S, Saadat A,. 2012b. A randomized controlled trial on the anti-inflammatory effects of curcumin in patients with chronic sulphur mustard-induced cutaneous complications. Ann Clin Biochem 49: 580-588.
55. Pearson TA, Denke MA, McBride PE, et al,. 2006. Effectiveness of ezetimibe added to ongoing statin therapy in modifying lipid profiles and low-density lipoprotein cholesterol goal attainment in patients of different races and ethnicities: a substudy of the ezetimibe add-on to statin for effectiveness trial. Mayo Clin Proc 81: 1177-1185.
56. Prasad K,. 2006. C-reactive protein (CRP)-lowering agents. Cardiovasc Drug Rev 24: 33-50.
57. Ridker PM, Cushman M, Stampfer MJ, Tracy RP, Hennekens CH,. 1997. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 336: 973-979.
58. Ridker PM, Cannon CP, Morrow D, et al,. 2005. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 352: 20-28.
59. Ridker PM, Danielson E, Fonseca FA, et al,. 2008. Rosuvastatin to prevent vascular events in men and women with elevated creactive protein. N Eng J Med 359: 2195-2207.
60. Ross R,. 1999. Atherosclerosis: an inflammatory disease. N Engl J Med 340: 115-126.
61. Sahebkar A,. 2010. Molecular mechanisms for curcumin benefits against ischemic injury. Fertil Steril 94: e75-76.
62. Sahebkar A,. 2011. Phosphatidylcholine-rich nanoliposomes: Potential tools for serum C-reactive protein reduction? Cardiovasc Drugs Ther 25: 105-106.
63. Sahebkar A,. 2012a. Why it is necessary to translate curcumin into clinical practice for the prevention and treatment of metabolic syndrome? Biofactors. doi: 10.1002/biof.1062.
64. Sahebkar A,. 2012b. Does PPARγ2 Gene Pro12Ala polymorphism affect nonalcoholic fatty liver disease risk? Evidence from a Meta-Analysis. DNA Cell Biol doi: 10.1089/dna.2012.1947.
65. Sahebkar A, Mohammadi A, Atabati A, et al,. 2013. Curcuminoids modulate pro-oxidant-antioxidant balance but not the immune response to heat shock protein 27 and oxidized LDL in obese individuals. Phytother Res. doi: 10.1002/ptr.4952
66. Sarvalkar PP, Walvekar MV, Bhopale LP,. 2011. Antioxidative effect of curcumin (Curcuma longa) on lipid peroxidation and lipofuscinogenesis in submandibular gland of D-galactose- induced aging male mice. J Med Plant Res 5: 5191-5193.
67. Schaffer M, Schaffer PM, Zidan J, Bar SG,. 2011. Curcuma as a functional food in the control of cancer and inflammation. Curr Opin Clin Nutr Metab Care 14: 588-597.
68. Shehzad A, Wahid F, Lee YS,. 2010. Curcumin in cancer chemoprevention: molecular targets, pharmacokinetics, bioavailability, and clinical trials. Arch Pharm (Weinheim) 343: 489-499.
69. Shehzad A, Ha T, Subhan F, Lee YS,. 2011. New mechanisms and the anti-inflammatory role of curcumin in obesity and obesity-related metabolic diseases. Eur J Nutr 50: 151-161.
70. Shehzad A, Rehman G, Lee YS,. 2013. Curcumin in inflammatory diseases. Biofactors 39: 69-77.
71. Shin SK, Ha TY, McGregor RA, Choi MS,. 2011. Long-term curcumin administration protects against atherosclerosis via hepatic regulation of lipoprotein cholesterol metabolism. Mol Nutr Food Res 55: 1829-1840.
72. Shishodia S, Amin HM, Lai R, Aggarwal BB,. 2005. Curcumin (diferuloylmethane) inhibits constitutive NF-kappaB activation, induces G1/S arrest, suppresses proliferation, and induces apoptosis in mantle cell lymphoma. Biochem Pharmacol 70: 700-713
73. Shoba G, Joy D, Joseph T, Majeed M, Rajendran R, Srinivas PS,. 1998. Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers. Planta Med 64: 353-356.
74. Slonim AE, Grovit M, Bulone L,. 2009. Effect of exclusion diet with nutraceutical therapy in juvenile Crohn's disease. J Am Coll Nutr 28: 277-285.
75. Srivastava G, Mehta JL,. 2009. Currying the heart: Curcumin and cardioprotection. J Cardiovasc Pharmacol Ther 14: 22-27.
76. Strimpakos AS, Sharma RA,. 2008. Curcumin: preventive and therapeutic properties in laboratory studies and clinical trials. Antioxid Redox Signal 10: 511-545.
77. Swamy AV, Gulliaya S, Thippeswamy A, Koti BC, Manjula DV,. 2012. Cardioprotective effect of curcumin against doxorubicin-induced myocardial toxicity in albino rats. Indian J Pharmacol 44: 73-77.
78. Taylor AJ, Sullenberger LE, Lee HJ, et al,. 2004. Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 110: 3512-3517.
79. Tousoulis D, Kampoli AM, Papageorgiou N, et al,. 2011. Pathophysiology of atherosclerosis: the role of inflammation. Curr Pharm Des 17: 4089-4110.
80. Urlimann J, Thorbecke G, Hochwald G,. 1966. The liver as the site of C-reactive protein formation. J Exp Med 123: 365-378.
81. Wongcharoen W, Phrommintikul A,. 2009. The protective role of curcumin in cardiovascular diseases. Int J Cardiol 133: 145-151.
82. Wongcharoen W, Jai-Aue S, Phrommintikul A, et al,. 2012. Effects of curcuminoids on frequency of acute myocardial infarction after coronary artery bypass grafting. Am J Cardiol 110: 40-44.
83. Yeh CH, Chen TP, Wu YC, Lin YM, Jing LP,. 2005. Inhibition of NFkappaB activation with curcumin attenuates plasma inflammatory cytokines surge and cardiomyocytic apoptosis following cardiac ischemia/reperfusion. J Surg Res 125: 109-116.
84. Yu H, Rifai N,. 2000. High-sensitivity C-reactive protein and atherosclerosis: from theory to therapy. Clin Biochem 33: 601-610.